Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 26, 2026
FUTU vs TIGR: Evaluating Two Prominent Asia-Focused Brokerage Platforms

FUTU vs TIGR: Evaluating Two Prominent Asia-Focused Brokerage Platforms

Key Takeaways

  • Both FUTU and TIGR are Asia-focused online brokerages that posted sharp double-digit revenue and profit growth in 2025, yet both stocks have pulled back from earlier highs.
  • FUTU is the larger and more profitable platform, with roughly 3.4 million funded accounts and a net margin near 50%, versus about 1.25 million funded customers for TIGR.
  • TIGR has grown faster off a smaller base, with net income rising sharply and strong traction in Singapore, Hong Kong, and Australia.
  • Both names carry concentrated exposure to Hong Kong and China equity sentiment, making them sensitive to the same macro and regulatory catalysts.
  • Relative performance diverged in recent months, with TIGR experiencing a steeper drawdown than FUTU despite comparable fundamental momentum.

Setting the Stage for These Digital Brokers

Futu Holdings and UP Fintech stand out among digital brokerage platforms, each running mobile-first apps aimed at retail investors in Greater China and Southeast Asia. Futu operates through its Futubull and moomoo applications, while UP Fintech runs Tiger Brokers. Given their overlapping focus on users, offerings, and regions, direct comparisons help clarify how differences in scale, margins, and positioning influence results. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry. The sections that follow examine recent financial results, performance trends, and risk considerations.

FUTU: Scale and Recent Results

Futu Holdings, based in Hong Kong, provides online brokerage, margin financing, wealth management, and IPO distribution services. For the full year 2025, revenue reached approximately HK$22.8 billion, reflecting roughly 68% year-over-year growth, while net income more than doubled. Funded accounts climbed to about 3.4 million, a 40% increase from the previous year, and client assets grew to roughly HK$1.23 trillion. Despite these solid figures, FUTU shares have come under pressure lately. Management pointed to a downturn in Hong Kong equities that affected asset values and slowed new client sign-ups there, even as activity picked up in Japan, Malaysia, and the United States. The stock’s mixed price action mirrors this balance of strong earnings against softer sentiment around China-linked financial names.

TIGR: Growth Trajectory and Market Moves

UP Fintech, parent of Tiger Brokers and headquartered in Singapore, offers equities, options, futures, wealth products, and crypto trading across global markets. Fiscal 2025 revenues rose 56.3% to around US$612 million, and net income attributable to ordinary shareholders surged roughly 181% to about US$170.9 million. Total account balances increased 45.7% to approximately US$60.8 billion, with deposit customers reaching about 1.25 million. Even so, TIGR has shown notable volatility and a sharper price decline than many peers. The firm has highlighted its shift since 2022 toward Singapore, Hong Kong, Australia, and New Zealand, where client assets have expanded quickly, along with underwriting 47 U.S. and Hong Kong IPOs. These strengths have not fully shielded the stock from broader caution around China-related financials.

Side-by-Side Analysis

Although the companies share similar models, their profiles differ meaningfully. FUTU benefits from greater scale, stronger profitability, and a leading position in Hong Kong among online brokers. Its higher net margin stems from operating leverage and a revenue mix that includes brokerage fees, interest income, and wealth management. TIGR, meanwhile, represents a smaller but faster-growing platform with deeper diversification into Singapore and Australia and greater emphasis on options, futures, and corporate services such as ESOP administration. Growth paths also vary: Futu has drawn broad client additions across several markets and rising wealth-management assets, while Tiger has targeted affluent, tech-oriented users and invested in self-clearing and AI-driven capabilities. Both remain exposed to regulatory oversight, geopolitical factors, and swings in trading volumes. At present, Futu appears steadier on margins and stability, whereas Tiger offers higher-beta exposure with a lower valuation but larger recent price decline.

AI Assessment of the Two Names

Considering factors such as trend consistency, earnings momentum, profitability, and relative stability, Tickeron’s AI framework would likely lean toward FUTU in the current setting. The larger scale, stronger margins, and steadier price behavior point to a more reliable trend profile, while Tiger’s deeper drawdown and higher volatility suggest a less settled near-term picture despite its growth numbers. This view remains probabilistic: renewed risk appetite toward China-linked financials could lift the higher-beta TIGR more sharply. I’m watching this closely as conditions change.

Exploring Tickeron’s AI Trading Bots

When evaluating systematic strategies for names like these, I often review Tickeron’s Trending AI Robots page, which highlights top-performing AI trading bots suited to current market conditions. These bots cover a range of approaches and timeframes, helping align tactics with personal risk preferences.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TIGR, FUTU

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


TIGR in +6.05% Uptrend, rising for three consecutive days on September 04, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TIGR advanced for three days, in 197 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Bearish Trend Analysis

The 10-day RSI Indicator for TIGR moved out of overbought territory on August 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 21 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TIGR as a result. In 67 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for TIGR turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

TIGR moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TIGR crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TIGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

TIGR broke above its upper Bollinger Band on August 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TIGR entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. TIGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.941) is normal, around the industry mean (4.579). P/E Ratio (9.656) is within average values for comparable stocks, (30.282). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (0.811). Dividend Yield (0.000) settles around the average of (0.016) among similar stocks. P/S Ratio (1.257) is also within normal values, averaging (16.763).

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TIGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Charles Schwab Corp (The) (NYSE:SCHW), Gold.com Inc. (NYSE:GOLD).

Industry description

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

Market Cap

The average market capitalization across the Investment Banks/Brokers Industry is 12.93B. The market cap for tickers in the group ranges from 590 to 308.32B. MS holds the highest valuation in this group at 308.32B. The lowest valued company is FSSLD at 590.

High and low price notable news

The average weekly price growth across all stocks in the Investment Banks/Brokers Industry was -1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 16%. NCPL experienced the highest price growth at 84%, while AXG experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Investment Banks/Brokers Industry was -49%. For the same stocks of the Industry, the average monthly volume growth was 30% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 65
P/E Growth Rating: 63
Price Growth Rating: 56
SMR Rating: 74
Profit Risk Rating: 86
Seasonality Score: -13 (-100 ... +100)
View a ticker or compare two or three
TIGR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of security brokerage services

Industry InvestmentBanksBrokers

Industry
Investment Banks Or Brokers
Address
No. 16 Taiyanggong Middle Road
Phone
+86 105 681-3666
Employees
1346
Web
https://www.itiger.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.